<DOC>
	<DOCNO>NCT00958893</DOCNO>
	<brief_summary>An open label , extension study subject complete ZPU-003 Ext 1 study .</brief_summary>
	<brief_title>An Extension Study Evaluating Safety Efficacy Proellex® In Women Who Have Previously Completed ZPU 003 Ext</brief_title>
	<detailed_description>This open label , extension study subject complete ZPU-003 Ext 1 study off-drug interval ( menses ) , prior start first 16-week dosing cycle . Subjects receive 50 mg Proellex® daily dose . Total study participation ZPU-003 Ext 2 ( Extension 2 ) may three 4 month drug cycle separate drug interval .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Four subject one site complete ZPU 003 Ext 1 study All subject</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine fibroid</keyword>
</DOC>